CTOs on the Move

Aerin Medical

www.aerinmedical.com

 
Aerin`s advanced treatment platform utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion. Treatment styluses are uniquely designed for each procedure and deliver energy to the target tissue surface without the need for incisions or tissue penetration.Proprietary algorithms ensure that targeted tissues are exposed to carefully controlled energy resulting in treatment temperatures that are below the tissue ablation range. The technology is protected by a comprehensive patent estate consisting of both method and design patents.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aerin Medical raised $15M on 12/13/2017
Aerin Medical raised $48M on 08/17/2020
Aerin Medical raised $38.8M on 05/03/2022

Similar Companies

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.

Cradle Genomics

At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.

Nova Biologics.

Nova Biologics. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ACM Global central laboratory

ACM Global central laboratory is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pillar Biosciences

Pillar Biosciences aims to "Make precision medicine the first option for every patient" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today`s high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%. Current as of May 25, 2021.